Nedosiran

Nedosiran is a pharmaceutical drug under investigation for the treatment of primary hyperoxaluria, a rare genetic disorder characterized by the overproduction of oxalate, which can lead to kidney stones and renal failure. Nedosiran is designed to inhibit the enzyme lactate dehydrogenase (LDH), which plays a key role in the metabolic pathway that produces oxalate.

Mechanism of Action

Nedosiran works by targeting and inhibiting LDH, an enzyme involved in the conversion of glycolate to glyoxylate, and subsequently to oxalate. By inhibiting LDH, nedosiran reduces the production of oxalate, thereby decreasing the risk of kidney stone formation and other complications associated with primary hyperoxaluria.

Clinical Development

Nedosiran is currently in clinical trials to evaluate its safety and efficacy in patients with primary hyperoxaluria. The drug has shown promise in early-phase trials, demonstrating a significant reduction in urinary oxalate levels in treated patients.

Administration

Nedosiran is administered via subcutaneous injection. The dosing regimen and frequency are determined based on the patient's condition and response to the treatment.

Side Effects

Common side effects of nedosiran may include injection site reactions, such as redness, swelling, and pain. Other potential side effects are being monitored and evaluated in ongoing clinical trials.

Related Conditions

• Primary hyperoxaluria
• Kidney stones
• Renal failure

See Also

• Lactate dehydrogenase
• Glycolate
• Glyoxylate
• Oxalate